Immunocore Holdings plc American Depositary Shares
IMCR
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Last trade$27.58
Day change-$1.30 (-4.50%)
Day range$27.54 – $29.10
Volume180,373
Market cap$1.49B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.49B
Price / earnings
—
Price / book
3.56×
Price / sales
3.48×
EV / sales
3.2×
EV / EBITDA
-54.78×
Profitability
Earnings per share
-$0.62
Return on assets
-2.84%
Return on equity
-7.65%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.94×
Current ratio
4.62×
Quick ratio
4.59×
Cash ratio
2.23×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$18.21M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for IMCR, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$102.22M
$115.93M
$106.68M
$104.48M
$103.69M
$97.96M
$93.88M
$84.05M
Cost of revenue
$676K
$1.09M
$434K
$2.7M
$513K
$1.04M
$831K
$330K
Gross profit
$101.55M
$114.84M
$106.24M
$101.78M
$103.18M
$96.92M
$93.05M
$83.72M
Selling, general and administrative
$40.45M
$43.89M
$37.85M
$42.65M
$39.78M
$42.79M
$40.2M
$42.32M
Research and development
$74.7M
$73.95M
$61.11M
$78.82M
$70.57M
$69.01M
$56.47M
$60.85M
Total operating expenses
$115.16M
$117.84M
$98.96M
$121.47M
$110.35M
$111.8M
$96.67M
$103.17M
Operating income
-$13.61M
-$3M
$7.28M
-$19.69M
-$7.17M
-$14.88M
-$3.62M
-$19.45M
Interest expense
-$3.06M
-$3.06M
-$3.05M
-$3.05M
-$3.04M
-$3.05M
-$3.03M
-$7.04M
Income before taxes
-$14.07M
-$514K
$13.27M
-$15.79M
$304K
-$9.69M
$6.08M
-$24.82M
Income taxes
$153K
$294K
$301K
$14.27M
$481K
$606K
$1.06M
-$1.05M
Net income
-$14.22M
-$808K
$12.97M
-$30.06M
-$177K
-$10.3M
$5.02M
-$23.77M
Net income attributable to common shareholders
-$14.22M
-$808K
$12.97M
-$30.06M
-$177K
-$10.3M
$5.02M
-$23.77M
EBITDA
-$12.5M
-$1.97M
$8.23M
-$18.86M
-$6.37M
-$14.1M
-$2.76M
-$18.29M
Basic earnings per share
-$0.28
-$0.02
$0.26
-$0.59
$0.00
-$0.20
$0.10
-$0.47
Diluted earnings per share
-$0.28
-$0.02
$0.25
-$0.62
$0.00
-$0.20
$0.10
-$0.50
Recent news
Company coverage with links to the original publishers.
Immunocore Holdings plc announced that management will participate in the UBS Global Biopharma Conference and Jefferies London Global Healthcare Conference in November 2026. The company will present its latest developments in TCR bispecific immunotherapies, including updates on KIMMTRAK, its approved treatment for uveal melanoma, which generated $102.2 million in Q3 2026 revenues.
Immunocore announced Phase 1/2 trial results showing a combination of brenetafusp and KIMMTRAK achieved a 70% two-year overall survival rate in 17 first-line metastatic uveal melanoma patients, with a 29% overall response rate and manageable safety profile. The company plans to initiate a Phase 2/3 randomized trial (DUET-UVEAL) to further evaluate the combination therapy.
Immunocore announced it will present Phase 1 data for brenetafusp combined with KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the 2026 SITC Annual Meeting. The presentation will showcase clinical data for the first combination of two T cell engagers in a solid tumor, with poster and oral sessions scheduled for November 6-7, 2026.
Immunocore announced it has enrolled 540 patients in the phase III TEBE-AM study evaluating Kimmtrak as monotherapy and in combination with Merck's Keytruda versus investigator's choice in previously treated advanced melanoma. The company expects top-line overall survival data as early as end of 2026. Kimmtrak sales grew 16% year-over-year to $222.6 million in the first half of 2026.
Immunocore Holdings plc announced that management will participate in multiple investor conferences in September 2026, including presentations at Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, Baird Global Healthcare Conference, and H.C. Wainwright Global Investment Conference. The company's lead product KIMMTRAK generated $115.9 million in Q2 2026 revenues, representing 18% year-over-year growth.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.